Patients Reluctant to Comply With Drug-Only Psychiatric Treatment

Share this content:
Patients Reluctant to Comply With Drug-Only Psychiatric Treatment
Patients Reluctant to Comply With Drug-Only Psychiatric Treatment

TUESDAY, March 7, 2017 (HealthDay News) -- Mental health patients are more likely to reject treatment if it involves only medication, according to a study published online March 6 in Psychotherapy.

Roger Greenberg, Ph.D., a professor of psychology at the State University of New York's Upstate Medical University in Syracuse, and colleagues analyzed 186 studies of patients who sought help for mental health conditions. Overall, the average treatment refusal rate was 8.2 percent.

Patients offered drug therapy alone were 1.76 times as likely to refuse treatment as those offered psychotherapy alone, the researchers found. Among patients who started treatment, more than one in five did not complete it. Again, patients on drug-only therapy were 1.20 times more likely to drop out of treatment early. Patients with depression were 2.16 times more likely to refuse drug therapy alone, and patients with panic disorders were 2.79 times more likely to refuse drug therapy alone.

"Patients often desire an opportunity to talk with and work through their problems with a caring individual who might be able to help them better face their emotional experiences," Greenberg said in a news release from the American Psychological Association. "Psychotropic medications may help a lot of people, and I think some do see them as a relatively easy and potentially quick fix, but I think others view their problems as more complex and worry that medications will only provide a temporary or surface level solution for the difficulties they are facing in their lives."

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »